• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    FDA Advisory Committee To Review Stealth`s Elamipretide For Barth Syndrome

    PR NEWSWIRE

    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth

    PR NEWSWIRE

    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD

    PR NEWSWIRE

    Stealth Biotherapeutics` Barth Syndrome NDA Receives Priority Review Designation

    PR NEWSWIRE

    Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug

    ENDPTS

    Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome

    PR NEWSWIRE

    Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide

    PR NEWSWIRE

    Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia

    PR NEWSWIRE

    Stealth granted FDA meeting to revive elamipretide filing

    FIERCEBIOTECH

    Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide

    PRNEWSWIRE

    Stealth BioTherapeutics Receives ODD for Elamipretide in DMD

    PRNEWSWIRE

    Stealth Bio Posts Disappointing Data From Mid-Stage Geographic Atrophy Study

    BENZINGA

    Stealth BioTherapeutics` Completes Phase 2 Geographic Atrophy Clinical Trial

    PRNEWSWIRE

    Stealth BioTherapeutics Announces Oral Presentation of New DMD Data

    PRNEWSWIRE

    Stealth rare disease drug denied by FDA in I told you so moment

    MARKETWATCH

    Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

    PRNEWSWIRE

    Stealth Elamipretide NDA Tests Frontiers Of FDA’s Flexibility In Rare Diseases

    PINK SHEET

    Stealth BioTherapeutics Announces Elamipretide Clinical Data

    PRNEWSWIRE

    Stealth Biotherapeutics Announces $20M Financing to Advance Elamipretide

    PRNEWSWIRE

    Stealth`s Announces +ve Results From Study to Evaluate Efficacy of Elamipretide

    PR NEWSWIRE

    Stealth BioTherapeutics Presents Data for Elamipretide

    PR NEWSWIRE

    Stealth CEO Share Excitement about Alexion Partnership and Potential of PMM Drug

    BIOSPACE

    Alexion bags option on Stealth`s phase 3 rare disease drug

    FIERCE PHARMA

    Stealth Announces Positive Results for Elamipretide in Ophthalmic Conditions

    PR NEWSWIRE

    Stealth Bio Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.